Cetuximab (Erbitux)

Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution.

Saved in:
Bibliographic Details
Published in:American journal of neuroradiology : AJNR 2010-04, Vol.31 (4), p.626-627
Main Authors: BOU-ASSALY, W, MUKHERJI, S
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - economics
Antibodies, Monoclonal - pharmacokinetics
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - adverse effects
Antineoplastic Agents - economics
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carcinoma, Squamous Cell - drug therapy
Cell Division - drug effects
Cetuximab
Colorectal Neoplasms - diagnostic imaging
Colorectal Neoplasms - drug therapy
Drug Approval
Drug Costs - statistics & numerical data
Drug Resistance, Neoplasm
ErbB Receptors - drug effects
Humans
Infusions, Intravenous
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Nervous system
Otorhinolaryngologic Neoplasms - diagnostic imaging
Otorhinolaryngologic Neoplasms - drug therapy
Pharmacology Vignette
Radiodiagnosis. Nmr imagery. Nmr spectrometry
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution.
ISSN:0195-6108
1936-959X
DOI:10.3174/ajnr.A2054